Cargando…

Sustained response off therapy after fostamatinib: A chronic refractory ITP case report

Fostamatinib is a SYK-inhibitor drug recently approved by the FDA and EMA for treating chronic immune thrombocytopenia. This drug induces a response in about 40% of patients and has a good toxicity profile. It is known that discontinuing thrombopoietin receptor agonists (TRAs) with the maintenance o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auteri, Giuseppe, Biondo, Mattia, Mazzoni, Camilla, Venturi, Marta, Romagnoli, Andrea Davide, Paglia, Simona, Cavo, Michele, Vianelli, Nicola, Palandri, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946849/ https://www.ncbi.nlm.nih.gov/pubmed/36846652 http://dx.doi.org/10.1016/j.heliyon.2023.e13462

Ejemplares similares

Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study
por: Auteri, Giuseppe, et al.
Publicado: (2023)

P1614: TAPERING SCHEME AND SUSTAINED RESPONSE IN PATIENTS WITH ITP TREATED WITH FOSTAMATINIB
por: Mingot-Castellano, María Eva, et al.
Publicado: (2023)

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
por: Vianelli, Nicola, et al.
Publicado: (2022)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion
por: Lucchesi, Alessandro, et al.
Publicado: (2023)

The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report
por: Auteri, Giuseppe, et al.
Publicado: (2021)

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
por: Palandri, Francesca, et al.
Publicado: (2021)

Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib
por: Innao, Vanessa, et al.
Publicado: (2023)

P1601: PREDICTING THE RESPONSE TO SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA (ITP): A MULTI-CENTRIC PILOT STUDY
por: Zoletto, Simone, et al.
Publicado: (2023)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
por: Barone, Martina, et al.
Publicado: (2020)

Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly
por: Sollazzo, Daria, et al.
Publicado: (2016)

Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic
por: Rodeghiero, Francesco, et al.
Publicado: (2021)

Refractory chronic “ITP”: When platelet size matters
por: Baliakas, Panagiotis, et al.
Publicado: (2018)

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34(+) Cells
por: Forte, Dorian, et al.
Publicado: (2018)

A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera
por: Barone, Martina, et al.
Publicado: (2021)

Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
por: Harbi, Maan H., et al.
Publicado: (2022)

Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism
por: Nedumannil, Rithin, et al.
Publicado: (2022)

An ITP workbook
por: Kalman, J A
Publicado: (1986)

Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study
por: Sollazzo, Daria, et al.
Publicado: (2016)

Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents
por: Lengel, Dave, et al.
Publicado: (2015)

Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020)

An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
por: Barone, Monica, et al.
Publicado: (2021)

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
por: Herman, SEM, et al.
Publicado: (2013)

ITP Conference on High T
por: Collective
Publicado: (2000)

Lenalidomide-Associated ITP
por: Herold, Christina I., et al.
Publicado: (2011)

Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
por: Lv, Yue, et al.
Publicado: (2022)

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406
por: Matsukane, Ryosuke, et al.
Publicado: (2022)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
por: Lee, Eun-Ju, et al.
Publicado: (2022)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
por: Palandri, Francesca, et al.
Publicado: (2023)

PB2619: THE IMPACT OF ITP-DIRECTED TREATMENT ON FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
por: Diraimo, Jennifer, et al.
Publicado: (2023)

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
por: Strüßmann, Tim, et al.
Publicado: (2022)

The automated reasoning system ITP
por: Lusk, E L, et al.
Publicado: (1984)

Rituximab resistance in ITP and beyond
por: Xiao, Zhengrui, et al.
Publicado: (2023)

The relevance of a low JAK2(V617F) allele burden in clinical practice: a monocentric study
por: Perricone, Margherita, et al.
Publicado: (2017)

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA
por: McKeage, Kate, et al.
Publicado: (2018)

Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib
por: Cooper, Nichola, et al.
Publicado: (2021)

S298: MATERNAL AND FETAL OUTCOMES IN PREGNANCIES OF WOMEN WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER RETROSPECTIVE OBSERVATIONAL ITP-NET ITALIAN STUDY
por: Carpenedo, Monica, et al.
Publicado: (2023)

Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic
por: Strich, Jeffrey R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7icaaa92jmklusfsfsui6e1ulr